OncoImmunin, Inc. was founded by Dr. Akira Komoriya and Dr. Beverly Packard in 1994. The Company has been issued three U.S. patents and one Australian patent on its proprietary design for protease inhibitors and fluorogenic substrates. Multiple new applications as well CIP and PCT applications are under review.

OncoImmunin, Inc. has designed, synthesized, validated, and patented a new class of protease substrates. Unique aspects of these molecules are: (1) incorporation of amino acid sequence information from both sides of protease cleavage sites (up to ten amino acid residues), thereby providing not only linear but three-dimensional specificity for proteases and (2) ability to cross intact cell membranes enabling measurement and inhibition of intracellular protease activities in living cells. Exploitation of elements of this latter point form the basis for OncoImmunin's patented design for the therapeutic delivery of peptide-based protease inhibitors as well as peptide-based inhibitors of other intracellular targets in sizes ranging up to twenty amino acids.

The Company, a graduate of the University of Maryland's Technology Advancement Program, is now located in Gaithersburg, MD.